Connect Biopharma Holdings Ltd - ADR

NASDAQ:CNTB   9:51:15 AM EDT
4.82
+0.16 (+3.55%)
Products, Regulatory, Earnings Announcements

Connect Biopharma Reports Positive Top-Line Results From Global Phase 2 Clinical Trial Of CBP-201

Published: 11/18/2021 23:22 GMT
Connect Biopharma Holdings Ltd - ADR (CNTB) - Connect Biopharma Reports Positive Top-line Results From the Global Phase 2 Clinical Trial of Cbp-201 in Patients With Moderate-to-severe Atopic Dermatitis.
Connect Biopharma Holdings Ltd - Intends to Initiate a Phase 3 Trial Program in Mid-2022.
Connect Biopharma Holdings Ltd - Primary Endpoint Met With All Three Cbp-201 Arms Achieving Significant Improvements.
Connect Biopharma - Significant Improvements Also Reported for Key Secondary Endpoints From Global Phase 2 Clinical Trial of Cbp-201.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.69

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.